ArticlePharmacoEconomics2023

Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland.

Michaela Carla Barbier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.